Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04436276

A Study of Ad26.COV2.S in Adults (COVID-19)

Covid-19 Prevention Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older

Clinical Trial Summary

The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination administered in one cohort in healthy adults aged greater than or equal to (>=) 18 to less than or equal to (<=) 55 years and in adults aged >= 65 years in good health with or without stable underlying conditions. The purpose of the study is also to assess the safety and reactogenicity of Ad26.COV2.S administered as ad hoc booster vaccination in healthy adults aged >= 18 to <= 55 years and in adults >= 65 years in good health with or without stable underlying conditions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04436276
Study type Interventional
Source Janssen Vaccines & Prevention B.V.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 15, 2020
Completion date February 21, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04640233 - Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection Phase 2/Phase 3
Completed NCT05091307 - A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults Phase 3
Completed NCT05122260 - PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray Phase 1
Recruiting NCT04858633 - Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 Phase 3
Completed NCT04908722 - A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults Phase 3
Recruiting NCT05437029 - Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray Phase 1
Active, not recruiting NCT04713488 - An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine Phase 1/Phase 2
Recruiting NCT04741061 - Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light Phase 3
Completed NCT04765384 - A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) Phase 2